View Aptamers 2016 Agenda

All talks will be held in the The Edward Boyle auditorium, The Jacqueline du Pré Music Building, St Hilda’s College (Oxford).


(Agenda is subject to change)


08.00-08.50: Registration, Networking, Exhibition and welcome coffee

08.50: Welcome and housekeeping

08.55: Opening by Professor Dr Beatrix Suess

09.00: INSOAP updates by Dr Sarah Shigdar

Session 1: SELEX – New technological developments
Chair Dr David Bunka

09.10: Professor Thomas Brown, University of Oxford, United Kingdom
Synthesis of chemically modified oligonucleotides for the production of high-affinity aptamers

09.40: Dr Gregory Penner, President & CEO, NeoVentures Biotechnology Inc, Canada
FRELEX. free-free selection of aptamers

10.10: Dr Nathalie Vollmer, Horiba Scientific, France
Multiplex quantification of small molecule targets with SPRi analysis

10.30: Refreshment break, exhibition, posters and networking

11.10: Professor Chin-Yih Hong, Graduate Institute of Biomedical Engineering, National Chung Hsing University, Taiwan
Multiplex Immunoassays Using ssDNA Aptamers Generated by Magnetic-Assisted Rapid Aptamer Selection (MARAS)

11.30: Dr Bill Jackson, Base Pair Biotechnologies, USA
Applications of newly discovered aptamers in a variety of biosensors and assay formats

11.50: Professor Darryl J Bornhop, Professor of Chemistry, Vanderbilt University, TN, USA
Backscattering interferometry marries aptamer-based assays to enable quantitation of nerve agent metabolites and human cytomegalovirus in urine at clinical relevant levels

12.10: Dr Michael Blank, AptaIT GmbH, Germany
Improved Aptamer Identification and Optimization by Usage of Next Generation Sequencing

12.30: Lunch, exhibition, posters and networking

Session 2: Small molecule binding aptamer–Characterization and their application for gene control
Chair Professor Darryl Bornhop

13.40: Dr Philip Johnson, York University, Canada
Understanding Ligand Binding by the Cocaine-Binding Aptamer

14.00: Professor Dr Jörg S Hartig, Department of Chemistry, University of Konstanz, Germany
Engineering of synthetic riboswitches based on ribozyme expression platforms

14.30: Professor Dr Beatrix Suess, Technische Universität Darmstadt, Germany
Application of aptamers in the control of alternative splicing by engineered riboswitches

15.00: Professor Dr Uli Hahn, Hamburg University, Germany
Aptamers to inhibit cancer cell adhesion

15.30: Refreshment break, exhibition, posters and networking

Session 3: Aptamers as diagnostic tools
Chair Professor Said Ismail

16.00: Dr David Bunka, The Aptamer Group, United Kingdom
Novel Based Aptamer Biomarker Discovery

16.30: Processor Tony Cass, Imperial College London, United Kingdom
Engineering Aptamers for Use in Biosensors and Point of Decision Testing

17.00: Dr Julian Tanner, University of Hong Kong, China
Progress in aptamer-mediated malaria diagnosis

17.20: Dr Ana María de Lucas Cerrillo, Centro de Astrobiología (INTA/CSIC), Spain
RNA and DNA aptamers targeting HCV CORE protein and its applicability to HCV diagnosis

17.40: Dr Marimuthu Citartan, Advanced Medical & Dental Institute (AMDI), Universiti Sains Malaysia, Malaysia
REPORA-6 RNA aptamer, an agent in the aptamer-based capture assay (AptaCapture) of Erythropoietin (EPO) in doping detection


19.15 Dinner (entry by ticket only)


08.50: Welcome and housekeeping

Session 4: Therapeutic aptamers
Chair Professor Beatrix Suess

9.00: Professor Yoshikazu Nakamura, RIBOMIC Inc, Japan
Dual therapeutic action of a neutralizing anti-FGF2 aptamer in bone diseases and bone cancer pain

09.30: Professor Nicola Stonehouse, University of Leeds, United Kingdom
Manipulating viral protein-protein interactions with RNA aptamers

10.00: Professor Said Ismail, University of Jordan, Jordan
Aptamers as Potential Tyrosine Kinase Inhibitors

10.30: Refreshment break, exhibition, posters and networking

11.00: Dr Sarah Shigdar, Deakin University, Australia
Aptamers as theranostic agents: the companion diagnostic test

11.30: Dr Sorah Yoon, Beckman Research Institute of City of Hope, USA
ApDCs (Aptamer Drug Conjugates) for targeted therapies in pancreatic cancer; from nucleic acid to chemotherapeutics

12.00: Mr Chao Liang, Hong Kong Baptist University, Hong Kong, China
Oligopeptide aptamer-modified chalcone derivative specifically targets Smurf1 in osteoblasts and promotes bone formation

12.20: Lunch, exhibition, posters and networking

Session 5: Technologies
Chair Dr Sarah Shigdar

13.10: Miguel AD Neves, Department of Chemistry, York University, Toronto, ON, M3J 1P3, Canada
The Cocaine-Binding Aptamer: Structural and Thermodynamic Analysis of Two-Site Binding and Stem Length Variation

13.30: Rajesh Ahirwar, Academy of Scientific and Innovative Research, Delhi, India
Aptamer-mediated detection and targeting of estrogen receptor positive cells in human breast cancer

13.50: Dr Zhaofeng Luo, Core Facility Center for Life Sciences, University of Science and Technology of China (USTC), Hefei, PR China
Monitoring the aptamer selection progress by Q-PCR amplification curve

14.10: Closing remarks by the Symposium Chair and discussion

14.30: Close and departure